SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 3 analyzed stories

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

Novo Nordisk said Wegovy pill sales reached 5.39 billion Danish crowns in the third quarter, up 53% from the prior quarter and above the 4.62 billion forecast. The company also improved its 2026 outlook, moving adjusted sales and operating profit guidance to between 2% growth and 2% decline.

Published:

Updated:

What happened

Novo Nordisk raised its full-year outlook for sales and operating profit to a range from 2% growth to 2% decline, compared with its earlier forecast of declines of up to 6%. It cited demand for the Wegovy pill and Ozempic. Third-quarter Wegovy pill sales were 5.39 billion Danish crowns, while U.S. injectable Wegovy sales fell 13%.

Global impact / market context

The stronger pill sales and improved outlook suggest demand is helping the company’s expected results. But the fall in U.S. injectable Wegovy sales shows that demand was not stronger across every product.

What to watch

  1. Check Novo’s next sales update for Wegovy pill sales, which matter because the company cited pill demand when raising its outlook.
  2. Check whether U.S. injectable Wegovy sales keep falling, since they were down 13%.
  3. Check whether Novo repeats or changes its outlook range of 2% growth to 2% decline, which shows how its expectations are developing.

Affected assets

  • Eli Lilly
  • Novo Nordisk

Evidence